logo

For the Inventor, By the Inventor

Great Dunmow, United Kingdom

Austin John Reeve

USPTO Granted Patents = 13

Average Co-Inventor Count = 5.2

ph-index = 6

Forward Citations = 150(Granted Patents)


Location History:

  • Essex, GB (1996)
  • Great Dunmow, GB (1994 - 2005)

Company Filing History:

goldMedal13 out of 2,405 
 
Merck Sharp + Dohme Corp.
 patents

Years Active: 1994-2005

Loading Chart...
13 patents (USPTO):Explore Patents
1. 6946461 - Imidazolophthalazine derivatives as ligands for GABAA receptors (2005-09-20),
2. 6465462 - Substituted triazolo pyridazine derivatives as inverse agonists of the GABAA&agr;5 receptor subtype (2002-10-15),
3. 6313125 - Therapeutically active 1,2,4-triazolo[4.,3-B] pyridazine derivatives as ligands for GABA receptors (2001-11-06),
4. 6262103 - Thienycyclohexanone derivatives as ligands of the GABAA &agr;5 receptor subtype (2001-07-17),
5. 6025374 - Azetidine, pyrrolidine and piperidine derivatives as 5HT1 receptor (2000-02-15),
6. 5981529 - Substituted indolylpropyl-piperazine derivatives as 5-HT.sub.1D .alpha. (1999-11-09),
7. 5889008 - Substituted 1-indolylpropyl-4-phenethylpiperazadine derivatives (1999-03-30),
8. 5854268 - Azetidine, pyrrolidine and piperidine derivatives (1998-12-29),
9. 5807857 - Piperazine, piperidine and tetrahydropyridine derivative of (1998-09-15),
10. 5567726 - Imidazole, Triazole and tetrazole derivatives (1996-10-22),
11. 5554629 - 4-substituted 1,2,4-triazole derivatives (1996-09-10),
12. 5510362 - Imidazole, triazole and tetrazole derivatives (1996-04-23),
13. 5317103 - Indole-substituted five-membered heteroaromatic compounds as 5-HT.sub.1 (1994-05-31),

Title: Austin John Reeve: Innovator in GABAA Receptor Research

Introduction

Austin John Reeve is a notable inventor based in Great Dunmow, GB. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that interact with GABAA receptors. With a total of 13 patents to his name, Reeve's work is recognized for its potential therapeutic benefits.

Latest Patents

Among his latest patents, Reeve has developed imidazolophthalazine derivatives that serve as ligands for GABAA receptors. These compounds are designed to act as partial or full inverse agonists of the α5 receptor subunit while minimizing activity at other receptor subunit binding sites. This innovation is particularly beneficial as a medicament for enhancing cognition while reducing or eliminating proconvulsant activity. Additionally, he has worked on substituted triazolo pyridazine derivatives that function as inverse agonists of the GABAA α5 receptor subtype.

Career Highlights

Reeve's career is marked by his association with Merck Sharp & Dohme Corp., where he has been instrumental in advancing research in neuropharmacology. His innovative approaches to drug design have garnered attention in the scientific community, contributing to the understanding of GABAA receptor modulation.

Collaborations

Throughout his career, Reeve has collaborated with esteemed colleagues, including Leslie Joseph Street and Francine Sternfeld. These partnerships have facilitated the exchange of ideas and fostered advancements in their shared field of research.

Conclusion

Austin John Reeve's contributions to the field of medicinal chemistry, particularly in the area of GABAA receptor research, highlight his innovative spirit and dedication to enhancing cognitive therapies. His work continues to pave the way for future advancements in pharmacological treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…